Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 771

Results For "CE"

8908 News Found

USFDA refuses to grant EUA to Covaxin for padeatric use
News | March 04, 2022

USFDA refuses to grant EUA to Covaxin for padeatric use

Covaxin is not approved in the USA for any age group


MIBCON NDC offers CO2 Optimisation module
Sustainability | March 04, 2022

MIBCON NDC offers CO2 Optimisation module

The CO2 Optimization module is one of the four modules (Product Costing, BoM Management, CO2 Optimization, Supplier Strategy) within the entire NDC Simulation Suite


Cipla gets approval from SEC to conduct Paxlovid trials
News | March 03, 2022

Cipla gets approval from SEC to conduct Paxlovid trials

Paxlovid consists of nirmatrelvir, which inhibits a SARS-CoV-2 protein to stop the virus from replicating, and ritonavir, which slows down nirmatrelvir’s breakdown to help it remain in the body for a longer period at higher concentrations


Brinton ties up with Scholl Wellness Company
News | March 03, 2022

Brinton ties up with Scholl Wellness Company

Brinton Pharmaceuticals enters exclusive sales and distribution rights of Scholl foot care products including Krack cream


IIFL AMC funds acquire stake in OmniActive Health Technologies
Startup | March 03, 2022

IIFL AMC funds acquire stake in OmniActive Health Technologies

OmniActive seeks to improve lives by enhancing nutrition and wellness through science and innovation


IHub-Data and IIIT-Hyderabad offer course on drug discovery
News | March 03, 2022

IHub-Data and IIIT-Hyderabad offer course on drug discovery

12-week certificate course commences on March 10th 2022


DCGI approves Themis Medicare's Viralex for Covid-19 treatment
News | March 03, 2022

DCGI approves Themis Medicare's Viralex for Covid-19 treatment

Viralex is an immunomodulatory agent with broad-spectrum antiviral properties. It enhances both innate & adaptive immunity and strengthens the body's defence response to viral infections


Limited impact of short-term disruptions, growth momentum to continue in FY 23
News | March 03, 2022

Limited impact of short-term disruptions, growth momentum to continue in FY 23

Large players are adequately capitalised to make bigger investments to adjust for the ongoing fundamental shift in market opportunities


WHO includes molnupiravir in its Covid-19 treatment guidelines
Biotech | March 03, 2022

WHO includes molnupiravir in its Covid-19 treatment guidelines

This ninth update of WHO’s guideline on therapeutics includes a recommendation that casirivimab-imdevimab not be used for patients infected with the Omicron variant


Merck KGaA reports higher profits on strong volumes across its businesses
News | March 03, 2022

Merck KGaA reports higher profits on strong volumes across its businesses

Company expects strong organic growth in sales, EBITDA in 2022